Abstract
COVID-19 and tuberculosis (TB) exhibit similar symptomatic presentation, clinical parameters and co-diagnosis increases COVID-19 mortality yet there is limited understanding of the mechanisms underlying their immunopathogenic interactions. Here we show by single-cell RNA-sequencing of 18,990 cells from whole blood uninfected or infected with Mycobacterium tuberculosis (Mtb), SARS-CoV-2, or both pathogens, their shared, distinct, and synergistic immunological interactions. The greatest transcriptional divergence occurred within monocytes and two neutrophil subsets at early timepoints of infection. Co-infection had the greatest synergistic effect 24 hours post-infection including enrichment of IFN-γ and TNF production, whilst 96 hours post-infection Mtb, SARS-CoV-2 and co-infection shared considerable pathway overlap. SARS-CoV-2 infection alone resulted in widespread cell death 96 hours post-infection, whilst Mtb and co-infection had enhanced cell survival at 96 hrs, sharing negative regulation of extrinsic apoptosis. Our findings elucidate potential pathways for targeted host-directed therapies, which is particularly crucial for settings where these pathogens are now endemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The COVID Profile study was supported by WHO Unity funds and WEHI Philanthropic funds. The funders had no role in study design, data collection and analysis. D.S. is supported by WEHI and NHMRC (2020750). A.K.C. is funded by WEHI, philanthropic donors, NHMRC (2020750) and the Australian Respiratory Council
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Acquisition of human blood samples and immunological investigations were approved by the Human Research Ethics Committee at the Walter and Eliza Hall Institute (WEHI HREC #18_09LR and #20/08) and Melbourne Health (RMH69108) as part of the COVID PROFILE study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos